HPK1 checkpoint inhibitor (AstraZeneca Pharmaceuticals)

N/A

Report date: 2025/03/20 16:10:01
NME

Base Information

Drug NameHPK1 checkpoint inhibitor (AstraZeneca Pharmaceuticals)
Drug Alias Namehematopoietic progenitor kinase 1 checkpoint inhibitor (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 1 inhibitors
TargetsMitogen-activated protein kinase kinase kinase kinase 1
Therapy Area/IndicationsColorectal NeoplasmsBreast NeoplasmsFibrosarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Pharmaceuticals Lp
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceuticals Lp
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsBreast NeoplasmsFibrosarcoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A